Bryan Luchs

Mar 21, 2024 | law360.com | Bryan Luchs |Mike Weir

Get instant access to the one-stop news source for business lawyers Register Now! Sign up now for free access to this content Enter your details below and select your area(s) of interest to stay ahead of the curve and receive Law360's daily newsletters Email (NOTE: Free email domains not supported) First Name Last Name PLEASE NOTE: A verification email will be sent to your address before you can access your trial. Password (at least 8 characters required) Confirm Password Select at least one...

Mar 21, 2024 | law360.co.uk | Bryan Luchs |Mike Weir

Get instant access to the one-stop news source for business lawyers Register Now! Sign up now for free access to this content Enter your details below and select your area(s) of interest to stay ahead of the curve and receive Law360's daily newsletters Email (NOTE: Free email domains not supported) First Name Last Name Job Title Phone PLEASE NOTE: A verification email will be sent to your address before you can access your trial. Password (at least 8 characters required) Confirm Password...

Feb 23, 2024 | jdsupra.com | Bryan Luchs

Growing demand for cancer drugs, along with patent expiries and AI innovation, are driving dealmaking in the red-hot oncology spaceGlobal spending on cancer medicines is set to reach US$375 billion by 2027, with innovation in drug discovery and development ramping up to meet rising demand. While the global biotech sector continues to grapple with elevated interest rates and plunging valuations, the oncology sector continues to attract dealmaker interest.